Short Interest in Vaccinex, Inc. (NASDAQ:VCNX) Expands By 157.1%

Vaccinex, Inc. (NASDAQ:VCNX) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totalling 16,200 shares, an increase of 157.1% from the March 31st total of 6,300 shares. Currently, 3.0% of the company’s shares are sold short. Based on an average daily volume of 13,200 shares, the days-to-cover ratio is currently 1.2 days.

Hedge Funds Weigh In On Vaccinex

An institutional investor recently bought a new position in Vaccinex stock. Armistice Capital LLC bought a new stake in shares of Vaccinex, Inc. (NASDAQ:VCNX) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 680,000 shares of the company’s stock, valued at approximately $768,000. Armistice Capital LLC owned about 15.45% of Vaccinex at the end of the most recent quarter. 50.11% of the stock is owned by institutional investors and hedge funds.

Vaccinex Price Performance

NASDAQ VCNX traded down $0.10 on Friday, reaching $5.83. The company had a trading volume of 12,339 shares, compared to its average volume of 11,539. The firm has a market capitalization of $7.17 million, a PE ratio of -0.06 and a beta of 0.74. Vaccinex has a 1 year low of $4.43 and a 1 year high of $100.80. The firm has a 50-day moving average of $7.33 and a 200-day moving average of $9.50.

Vaccinex (NASDAQ:VCNX) last released its quarterly earnings results on Tuesday, April 2nd. The company reported ($39.40) earnings per share for the quarter.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.